Latest Headlines

Latest Headlines

Altheos grabs $12.5M more, launches glaucoma trial

Drug developer Altheos has expanded its Series A round by an additional $12.5 million, just in time for the launch of a Phase IIa dosing trial for its glaucoma treatment. The South San Francisco

Glaucoma drug focus inspires $20M A round for Altheos

The South San Francisco-based startup Altheos has garnered $20 million in Series A cash to push a glaucoma drug program licensed in from Japan's Asahi Kasei Pharma. That money will be put to use